HTR2A is associated with SSRI response in major depressive disorder in a Japanese Cohort

NeuroMolecular Medicine

Volumn 12, Issue 3, 2010, Pages 237-242

  Kishi, Taro ^a   Yoshimura, Reiji ^b   Kitajima, Tsuyoshi ^a   Okochi, Tomo ^a   Okumura, Takenori ^a   Tsunoka, Tomoko ^a   Yamanouchi, Yoshio ^a   Kinoshita, Yoko ^a   Kawashima, Kunihiro ^a   Naitoh, Hiroshi ^a   Nakamura, Jun ^b   Ozaki, Norio ^c   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Major depressive disorder; Selective serotonin reuptake inhibitor (SSRI) response; Serotonin 2A receptor gene (HTR2A); SNPs

Indexed keywords

FLUVOXAMINE; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHENOTYPE; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FLUVOXAMINE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 78649939577     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12017-009-8105-y     Document Type: Article

References (28)

1. Bowden, C. L. (2001). Strategies to reduce misdiagnosis of bipolar depression. Psychiatric Services, 52(1), 51-55.
2. Dudbridge, F. (2003). Pedigree disequilibrium tests for multilocus haplotypes. Genetic Epidemiology, 25(2), 115-121.
3. Kasper, S., Dotsch, M., Kick, H., Vieira, A., & Moller, H. J. (1993). Plasma concentrations of fluvoxamine and maprotiline in major depression: Implications on therapeutic efficacy and side effects. European Neuropsychopharmacology, 3(1), 13-21.
4. Kato, T. (2007). Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neurosciences, 61(1), 3-19.
5. Kato, M., Fukuda, T., Wakeno, M., Fukuda, K., Okugawa, G., Ikenaga, Y., et al. (2006). Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology, 53(4), 186-195.
6. Kato, M., & Serretti, A. (2008). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry (in press).
7. Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., et al. (2009a). Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. European Archives of Psychiatry and Clinical Neuroscience, 259(5), 293-297.
8. Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., et al. (2009b). CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Medicine, 11(2), 53-57.
9. Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., et al. (2008). Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. Neuroscience Research, 62(4), 211-215.
10. Kishi, T., Kitajima, T., Tsunoka, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., et al. (2009c). Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neuroscience Research, 64(2), 231-234.
11. Kishi, T., Kitajima, T., Tsunoka, T., Okumura, T., Ikeda, M., Okochi, T., et al. (2009d). Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. Neuromolecular Medicine, 11(2), 114-122.
12. McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics, 78(5), 804-814.
13. Myers, R. L., Airey, D. C., Manier, D. H., Shelton, R. C., & Sanders-Bush, E. (2007). Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biological Psychiatry, 61(2), 167-173.
14. Perlis, R. H., Fijal, B., Adams, D. H., Sutton, V. K., Trivedi, M. H., & Houston, J. P. (2009). Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological Psychiatry, 65(9), 785-791.
15. Peters, E. J., Slager, S. L., Jenkins, G. D., Reinalda, M. S., Garriock, H. A., Shyn, S. I., et al. (2009). Resequencing of serotonin- related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics, 19(1), 1-10.
16. Peveler, R., & Kendrick, T. (2005). Selective serotonin reuptake inhibitors: THREAD trial may show way forward. British Medical Journal, 330(7488), 420-421.
17. Purcell, S., Cherny, S. S., & Sham, P. C. (2003). Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics, 19(1), 149-150.
18. Saito, S., Takahashi, N., Ishihara, R., Ikeda, M., Suzuki, T., Kitajima, T., et al. (2006). Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. Neuropsychobiology, 54(4), 226-230.
19. Sato, K., Yoshida, K., Takahashi, H., Ito, K., Kamata, M., Higuchi, H., et al. (2002). Association between-1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology, 46(3), 136-140.
20. Serretti, A., & Artioli, P. (2004a). From molecular biology to pharmacogenetics: A review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl), 174(4), 490-503.
21. Serretti, A., & Artioli, P. (2004b). The pharmacogenomics of selective serotonin reuptake inhibitors. The Pharmacogenomics Journal, 4(4), 233-244.
22. Serretti, A., Calati, R., Giegling, I., Hartmann, A. M., Moller, H. J., Colombo, C., et al. (2007a). 5-HT2A SNPs and the Temperament and Character Inventory. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(6), 1275-1281.
23. Serretti, A., Drago, A., & De Ronchi, D. (2007b). HTR2A gene variants and psychiatric disorders: A review of current literature and selection of SNPs for future studies. Current Medicinal Chemistry, 14(19), 2053-2069.
24. Serretti, A., & Mandelli, L. (2008). The genetics of bipolar disorder: Genome 'hot regions', genes, new potential candidates and future directions. Molecular Psychiatry, 13(8), 742-771.
25. Spurlock, G., Heils, A., Holmans, P., Williams, J., D'Souza, U. M., Cardno, A., et al. (1998). A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Molecular Psychiatry, 3(1), 42-49.
26. Stensland, M. D., Schultz, J. F., & Frytak, J. R. (2008). Diagnosis of unipolar depression following initial identification of bipolar disorder: A common and costly misdiagnosis. Journal of Clinical Psychiatry, 69(5), 749-758.
27. Wilkie, M. J., Smith, G., Day, R. K., Matthews, K., Smith, D., Blackwood, D., et al. (2008). Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antide-pressant therapy. The Pharmacogenomics Journal.
28. Williams, J. B. (1988). A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry, 45(8), 742-747.